Company profile for NeuroDerm

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NeuroDerm is an agile, entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions. By integrating the unique, complementary strengths and diverse capabilities of Pharma and MedTech under one roof, we create synergies and value in the space between existing drugs and innovative treatments and technologies. We develop next-generation drug-device combination solutions for central nervous system di...
NeuroDerm is an agile, entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions. By integrating the unique, complementary strengths and diverse capabilities of Pharma and MedTech under one roof, we create synergies and value in the space between existing drugs and innovative treatments and technologies. We develop next-generation drug-device combination solutions for central nervous system disorders through proprietary drug formulations, state of the art delivery systems and digital health technologies, connecting them all into a comprehensive solution for the benefit of patients and healthcare.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
3 Haim Pekeris Street, Ruhrberg Science Bldg. Bell Entrance, 4th floor, Rabin ...
Telephone
Telephone
+97289462729
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-highlights-parkinsons-disease-research-at-2025-ean-and-atmrd-congresses-302486508.html

PR NEWSWIRE
20 Jun 2025

https://www.prnewswire.com/news-releases/neuroderm-announces-highly-positive-results-from-the-pivotal-phase-iii-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-301715860.html

PR NEWSWIRE
09 Jan 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty